{"id":"relma-cel","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Hematologic toxicity"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL509173","moleculeType":"Small molecule","molecularWeight":"976.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Relma-cel involves engineering a patient's own T lymphocytes to express a chimeric antigen receptor (CAR) targeting a tumor-associated antigen, enabling the modified cells to recognize, proliferate, and destroy malignant cells. The CAR-T cells are expanded ex vivo and reinfused into the patient where they persist and provide durable anti-tumor immunity. This approach leverages the patient's immune system for targeted cancer cell elimination.","oneSentence":"Relma-cel is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:04:33.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)"}]},"trialDetails":[{"nctId":"NCT07077512","phase":"PHASE2","title":"Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":"Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)","enrollment":30},{"nctId":"NCT07326371","phase":"PHASE2","title":"Glofitamab Combined With CAR-T Therapy in R/R DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":24},{"nctId":"NCT06365671","phase":"PHASE2","title":"CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-04-16","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":16},{"nctId":"NCT07198464","phase":"NA","title":"Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Zhengzhou University","startDate":"2025-10-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL)","enrollment":30},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT06876688","phase":"PHASE2","title":"Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-11-30","conditions":"CNS Lymphoma","enrollment":30},{"nctId":"NCT06093841","phase":"PHASE2","title":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2023-11-03","conditions":"Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma","enrollment":46},{"nctId":"NCT05806580","phase":"PHASE4","title":"Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-05-01","conditions":"Relapsed or Refractory B-cell Lymphoma","enrollment":8},{"nctId":"NCT06149169","phase":"PHASE2","title":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2023-08-17","conditions":"Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma","enrollment":10},{"nctId":"NCT06479356","phase":"PHASE2","title":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2024-08-15","conditions":"Non-Hodgkin Lymphoma, Large B-cell Lymphoma","enrollment":12},{"nctId":"NCT06414135","phase":"PHASE1","title":"Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis","status":"RECRUITING","sponsor":"Liangjing Lu","startDate":"2024-06-12","conditions":"Systemic Sclerosis","enrollment":6},{"nctId":"NCT06142175","phase":"","title":"Relmacabtagene Autoleucel in Patients With LBCL","status":"UNKNOWN","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2022-12-28","conditions":"Large B-cell Lymphoma","enrollment":200},{"nctId":"NCT06297408","phase":"PHASE1","title":"Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2024-03","conditions":"Systemic Lupus Erythematosus","enrollment":24},{"nctId":"NCT05370547","phase":"PHASE1, PHASE2","title":"Chidamide Bridging for CAR-T Therapy","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2022-05-25","conditions":"Non Hodgkin's Lymphoma","enrollment":120},{"nctId":"NCT05590221","phase":"PHASE2","title":"Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-01-03","conditions":"B-cell Lymphoma","enrollment":20},{"nctId":"NCT05259813","phase":"PHASE1","title":"Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL","status":"WITHDRAWN","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2022-02-28","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":""},{"nctId":"NCT04812691","phase":"PHASE1","title":"CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2020-07-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":12},{"nctId":"NCT06142188","phase":"","title":"Relmacabtagene Autoleucel in Hematologic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2023-12-28","conditions":"Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma","enrollment":150},{"nctId":"NCT05814848","phase":"PHASE4","title":"A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2023-06-20","conditions":"Relapsed or Refractory B-cell Lymphoma","enrollment":13},{"nctId":"NCT05765006","phase":"PHASE1","title":"CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus","status":"UNKNOWN","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2023-02-24","conditions":"Systemic Lupus Erythematosus","enrollment":24},{"nctId":"NCT03344367","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2017-11-16","conditions":"Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03355859","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Zhao Weili","startDate":"2018-01-05","conditions":"Non Hodgkin Lymphoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CD19-targeted Chimeric Antigen Receptor(CAR) T Cells","JWCAR029","if necessary can add other anti-SLE treatment such as corticosteroids, immunosuppressants, biologics"],"phase":"marketed","status":"active","brandName":"Relma-cel","genericName":"Relma-cel","companyName":"Shanghai Ming Ju Biotechnology Co., Ltd.","companyId":"shanghai-ming-ju-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Relma-cel is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}